Stoke Therapeutics, Inc. STOK EBITDA margin
EBITDA margin at other companies
Other financials
Where this comes from
Calculated from Stoke Therapeutics, Inc.’s reported figures.
Based on trailing twelve months.
The official record: Stoke Therapeutics, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Stoke Therapeutics, Inc.'s ebitda margin.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Stoke Therapeutics, Inc.'s EBITDA margin?
- Stoke Therapeutics, Inc. (STOK) reported EBITDA margin of -572.1% in Q1 2026.
- How has Stoke Therapeutics, Inc.'s EBITDA margin changed year-over-year?
- Stoke Therapeutics, Inc.'s EBITDA margin decreased by 2807.7% year-over-year, from 21.1% to -572.1%.
- What is the long-term trend for Stoke Therapeutics, Inc.'s EBITDA margin?
- Over 3 years (2022 to 2025), Stoke Therapeutics, Inc.'s EBITDA margin has grown at a -76.9% compound annual growth rate (CAGR), from -828.9% to -10.2%.
- What does EBITDA margin mean?
- EBITDA (earnings before interest, taxes, depreciation, and amortization) as a percentage of revenue, trailing twelve months. A proxy for cash operating profitability that strips out capital-structure and non-cash charges.